Discovery of Novel Isofunctional SARS-CoV-2 NSP14 RNA Cap Methyltransferase Inhibitors by Structure-Based Virtual Screening
In early 2020, SARS-CoV-2 spread into a worldwide pandemic, causing more than 7 million deaths. Direct-acting antivirals (DAAs) complementing vaccines and mitigating severe disease in at-risk populations remain important. Here, we used a structure-based virtual screening (SBVS) workflow to identify new SAH-dependent inhibitors of the SARS-CoV-2 RNA cap methyltransferase NSP14. We virtually screened the Enamine and Sigma in-stock screening collections as well as the 3 orders of magnitude larger Enamine REAL make-on-demand compound library, which produced better docking scores and higher virtual hit rates. While biochemical testing of 145 in-stock library compounds yielded a single NSP14-specific inhibitor, 123 chemically synthesized Enamine REAL SBVS compounds contained 10 hits specifically inhibiting NSP14 with half-maximal inhibitory concentrations (IC<sub>50</sub>) below 10 μM. The new compounds were chemically distinct in atomic composition from any NSP14 inhibitors previously identified by conventional biochemical high-throughput screening (HTS) and may serve as starting points to develop novel SARS-CoV-2 DAAs.
Authors
- David J. Huggins (ORCID: https://orcid.org/0000-0003-1579-2496)
- Cindy Meyer (ORCID: https://orcid.org/0000-0003-3807-8383)
- Hans-Heinrich Hoffmann (ORCID: https://orcid.org/0000-0003-0554-0244)
- Charles M. Rice (ORCID: https://orcid.org/0000-0003-3087-8079)
- Aitor Garzia (ORCID: https://orcid.org/0000-0002-6270-1369)
- Joshua Saul Davis (ORCID: https://orcid.org/0000-0001-9864-5699)
- Oleg M. Ganichkin
- Peter T. Meinke (ORCID: https://orcid.org/0000-0002-7548-6215)
- Thomas Tuschl (ORCID: https://orcid.org/0000-0002-6483-5678)
- Nigel J. Liverton (ORCID: https://orcid.org/0000-0002-3259-4558)
- Stefan Steinbacher (ORCID: https://orcid.org/0000-0002-4224-8317)
- Joseph Fraser Glickman (ORCID: https://orcid.org/0000-0002-6706-4039)
- Mayako Michino (ORCID: https://orcid.org/0000-0002-5469-025X)
- Michael W. Miller
- Julius Nitsche
Institutions
- Cornell University (US)
- ProterixBio (United States) (US)
- Tri-Institutional Therapeutics Discovery Institute (US)
- Rockefeller University (US)
Publication Details
- Journal
- ACS Medicinal Chemistry Letters
- Published
- 2025-08-15
- DOI
- https://doi.org/10.1021/acsmedchemlett.5c00339
- Primary Topic
- RNA and protein synthesis mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Rockefeller University
- Stavros Niarchos Foundation